IRON vs XENE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IRON · Disc Medicine$75.14 ▼ 1.27%
XENE · Xenon Pharmaceuticals$37.04 ▼ 1.38%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IRON -20.2%
- XENE -11.9%
Head to head
| Metric | IRON | XENE |
|---|---|---|
| Price | $75.14 | $37.04 |
| Change today | ▼ 1.27% | ▼ 1.38% |
| Market cap | $3.42B | $3.64B |
| Return, 3 months | -7.2% | -38.8% |
| Return, year to date | -5.4% | -17.4% |
| Return, 1 year | -18.9% | -10.0% |
| P/E (TTM) | – | – |
| P/B | 5.7 | 3.2 |
| P/E percentile vs own 5y | 46th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +4.5% | -21.5% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -41.3% | -50.3% |
| Analyst target vs. price | +66.4% | +98.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 47 | 41 |
| 30-day volatility | 108.4% | 39.0% |
| Max drawdown, 1 year | -40.8% | -52.8% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- XENE is the largest of the group by market value.
- XENE has returned the most over the past year.
- XENE has been the calmest stock over the last 30 days.